Al-Samkari H, van Beers EJ, D Morton H, Barcellini W, Eber SW, Glader B, Yaish HM, Chonat S, Kuo KHM, Kollmar N et al..  2020.  Characterization of the severe phenotype of pyruvate kinase deficiency.. Am J Hematol.

Al-Samkari H, van Beers EJ, D Morton H, Barcellini W, Eber SW, Glader B, Yaish HM, Chonat S, Kuo KHM, Kollmar N et al..  2020.  Characterization of the severe phenotype of pyruvate kinase deficiency.. Am J Hematol.

Grace RF, Bianchi P, van Beers EJ, Eber SW, Glader B, Yaish HM, Despotovic JM, Rothman JA, Sharma M, McNaull MM et al..  2018.  Clinical spectrum of pyruvate kinase deficiency: data from the Pyruvate Kinase Deficiency Natural History Study.. Blood. 131(20):2183-2192.

Grace RF, Bianchi P, van Beers EJ, Eber SW, Glader B, Yaish HM, Despotovic JM, Rothman JA, Sharma M, McNaull MM et al..  2018.  Clinical spectrum of pyruvate kinase deficiency: data from the Pyruvate Kinase Deficiency Natural History Study.. Blood. 131(20):2183-2192.

Frangoul H, Altshuler D, M Cappellini D, Chen Y-S, Domm J, Eustace BK, Foell J, de la Fuente J, Grupp S, Handgretinger R et al..  2021.  CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia.. N Engl J Med. 384(3):252-260.

Hoshino A, Kim HSang, Bojmar L, Gyan KEnnu, Cioffi M, Hernandez J, Zambirinis CP, Rodrigues G, Molina H, Heissel S et al..  2020.  Extracellular Vesicle and Particle Biomarkers Define Multiple Human Cancers.. Cell. 182(4):1044-1061.e18.

Hoshino A, Kim HSang, Bojmar L, Gyan KEnnu, Cioffi M, Hernandez J, Zambirinis CP, Rodrigues G, Molina H, Heissel S et al..  2020.  Extracellular Vesicle and Particle Biomarkers Define Multiple Human Cancers.. Cell. 182(4):1044-1061.e18.

Hoshino A, Kim HSang, Bojmar L, Gyan KEnnu, Cioffi M, Hernandez J, Zambirinis CP, Rodrigues G, Molina H, Heissel S et al..  2020.  Extracellular Vesicle and Particle Biomarkers Define Multiple Human Cancers.. Cell. 182(4):1044-1061.e18.

Hoshino A, Kim HSang, Bojmar L, Gyan KEnnu, Cioffi M, Hernandez J, Zambirinis CP, Rodrigues G, Molina H, Heissel S et al..  2020.  Extracellular Vesicle and Particle Biomarkers Define Multiple Human Cancers.. Cell. 182(4):1044-1061.e18.

Hoshino A, Kim HSang, Bojmar L, Gyan KEnnu, Cioffi M, Hernandez J, Zambirinis CP, Rodrigues G, Molina H, Heissel S et al..  2020.  Extracellular Vesicle and Particle Biomarkers Define Multiple Human Cancers.. Cell. 182(4):1044-1061.e18.

Hoshino A, Kim HSang, Bojmar L, Gyan KEnnu, Cioffi M, Hernandez J, Zambirinis CP, Rodrigues G, Molina H, Heissel S et al..  2020.  Extracellular Vesicle and Particle Biomarkers Define Multiple Human Cancers.. Cell. 182(4):1044-1061.e18.

Hoshino A, Kim HSang, Bojmar L, Gyan KEnnu, Cioffi M, Hernandez J, Zambirinis CP, Rodrigues G, Molina H, Heissel S et al..  2020.  Extracellular Vesicle and Particle Biomarkers Define Multiple Human Cancers.. Cell. 182(4):1044-1061.e18.

Al-Samkari H, van Beers EJ, D Morton H, Eber SW, Chonat S, Kuo KHM, Kollmar N, Wang H, Breakey VR, Sheth S et al..  2022.  Health-related quality of life and fatigue in children and adults with pyruvate kinase deficiency.. Blood Adv. 6(6):1844-1853.

Mensah C, Sheth S.  2021.  Optimal strategies for carrier screening and prenatal diagnosis of α- and β-thalassemia.. Hematology Am Soc Hematol Educ Program. 2021(1):607-613.

van Beers EJ, van Straaten S, D Morton H, Barcellini W, Eber SW, Glader B, Yaish HM, Chonat S, Kwiatkowski JL, Rothman JA et al..  2019.  Prevalence and management of iron overload in pyruvate kinase deficiency: report from the Pyruvate Kinase Deficiency Natural History Study.. Haematologica. 104(2):e51-e53.

van Beers EJ, van Straaten S, D Morton H, Barcellini W, Eber SW, Glader B, Yaish HM, Chonat S, Kwiatkowski JL, Rothman JA et al..  2019.  Prevalence and management of iron overload in pyruvate kinase deficiency: report from the Pyruvate Kinase Deficiency Natural History Study.. Haematologica. 104(2):e51-e53.

Rapido F, Brittenham GM, Bandyopadhyay S, La Carpia F, L'Acqua C, McMahon DJ, Rebbaa A, Wojczyk BS, Netterwald J, Wang H et al..  2017.  Prolonged Red Cell Storage Before Transfusion Increases Extravascular Hemolysis. J Clin Invest. 127(1):375-382.

Chonat S, Eber SW, Holzhauer S, Kollmar N, D Morton H, Glader B, Neufeld EJ, Yaish HM, Rothman JA, Sharma M et al..  2021.  Pyruvate kinase deficiency in children.. Pediatr Blood Cancer. 68(9):e29148.

Jafari R, Sheth S, Spincemaille P, Nguyen TD, Prince MR, Wen Y, Guo Y, Deh K, Liu Z, Margolis D et al..  2019.  Rapid automated liver quantitative susceptibility mapping.. J Magn Reson Imaging. 50(3):725-732.

L'Acqua C, Bandyopadhyay S, Francis RO, McMahon DJ, Nellis M, Sheth S, Kernie SG, Brittenham GM, Spitalnik SL, Hod EA.  2015.  Red Blood Cell Transfusion is Associated with Increased Hemolysis and an Acute Phase Response in a Subset of Critically Ill Children. Am J Hematol. 90(10):915-20.

Grace RF, Rose C, D Layton M, Galactéros F, Barcellini W, D Morton H, van Beers EJ, Yaish H, Ravindranath Y, Kuo KHM et al..  2019.  Safety and Efficacy of Mitapivat in Pyruvate Kinase Deficiency.. N Engl J Med. 381(10):933-944.

Betts M, Flight PA, L Paramore C, Tian L, Milenković D, Sheth S.  2020.  Systematic Literature Review of the Burden of Disease and Treatment for Transfusion-dependent β-Thalassemia.. Clin Ther. 42(2):322-337.e2.